New Australian Trial With Cannabis for Dementia

MGC Pharmaceuticals gets approval for its cannabis dementia drug trial
  • The company’s medical cannabis product, CogniCann, was granted approval to carry out the Phase IIB trials by Australia’s Therapeutic Goods Administration.
  • The product has been specifically developed for treating dementia as well as memory loss in Alzheimer’s patients.


Leave a Reply

Your email address will not be published. Required fields are marked *